142 related articles for article (PubMed ID: 24612435)
1. A novel mutation in the P2Y12 receptor and a function-reducing polymorphism in protease-activated receptor 1 in a patient with chronic bleeding.
Patel YM; Lordkipanidzé M; Lowe GC; Nisar SP; Garner K; Stockley J; Daly ME; Mitchell M; Watson SP; Austin SK; Mundell SJ
J Thromb Haemost; 2014 May; 12(5):716-25. PubMed ID: 24612435
[TBL] [Abstract][Full Text] [Related]
2. The DRY motif at work: the P2Y12 receptor case.
Rovati GE; Capra V
J Thromb Haemost; 2014 May; 12(5):713-5. PubMed ID: 24589132
[No Abstract] [Full Text] [Related]
3. Receptor homodimerization plays a critical role in a novel dominant negative P2RY12 variant identified in a family with severe bleeding.
Mundell SJ; Rabbolini D; Gabrielli S; Chen Q; Aungraheeta R; Hutchinson JL; Kilo T; Mackay J; Ward CM; Stevenson W; Morel-Kopp MC
J Thromb Haemost; 2018 Jan; 16(1):44-53. PubMed ID: 29117459
[TBL] [Abstract][Full Text] [Related]
4. The P2 receptors and congenital platelet function defects.
Cattaneo M
Semin Thromb Hemost; 2005 Apr; 31(2):168-73. PubMed ID: 15852220
[TBL] [Abstract][Full Text] [Related]
5. The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y
Whitley MJ; Henke DM; Ghazi A; Nieman M; Stoller M; Simon LM; Chen E; Vesci J; Holinstat M; McKenzie SE; Shaw CA; Edelstein LC; Bray PF
J Thromb Haemost; 2018 Dec; 16(12):2501-2514. PubMed ID: 30347494
[TBL] [Abstract][Full Text] [Related]
6. Succinate reverses in-vitro platelet inhibition by acetylsalicylic acid and P2Y receptor antagonists.
Spath B; Hansen A; Bokemeyer C; Langer F
Platelets; 2012; 23(1):60-8. PubMed ID: 21736422
[TBL] [Abstract][Full Text] [Related]
7. D121 Located within the DRY Motif of P2Y12 Is Essential for P2Y12-Mediated Platelet Function.
Dangelmaier C; Mauri B; Patel A; Kunapuli SP; Kostyak JC
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232816
[TBL] [Abstract][Full Text] [Related]
8. Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism.
Jakubowski JA; Zhou C; Egan B; Wells M; Kotob-Yahfoufi M; Sugidachi A; Dahlen JR
Platelets; 2011; 22(8):619-25. PubMed ID: 21639823
[TBL] [Abstract][Full Text] [Related]
9. Protease-activated receptor-4 and purinergic receptor P2Y12 dimerize, co-internalize, and activate Akt signaling via endosomal recruitment of β-arrestin.
Smith TH; Li JG; Dores MR; Trejo J
J Biol Chem; 2017 Aug; 292(33):13867-13878. PubMed ID: 28652403
[TBL] [Abstract][Full Text] [Related]
10. Influence of P2Y12 polymorphisms on platelet activity but not ex-vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects.
Li MP; Tang J; Wen ZP; Zhang YJ; Zhang W; Zhou HH; Zhang ZL; Chen XP
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):874-81. PubMed ID: 26083990
[TBL] [Abstract][Full Text] [Related]
11. Role of GRK6 in the Regulation of Platelet Activation through Selective G Protein-Coupled Receptor (GPCR) Desensitization.
Chaudhary PK; Kim S; Jee Y; Lee SH; Park KM; Kim S
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486261
[TBL] [Abstract][Full Text] [Related]
12. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
13. Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides.
Delierneux C; Donis N; Servais L; Wéra O; Lecut C; Vandereyken M; Musumeci L; Rahmouni S; Schneider J; Eble JA; Lancellotti P; Oury C
J Thromb Haemost; 2017 May; 15(5):983-997. PubMed ID: 28296036
[TBL] [Abstract][Full Text] [Related]
14. Rapid resensitization of purinergic receptor function in human platelets.
Mundell SJ; Barton JF; Mayo-Martin MB; Hardy AR; Poole AW
J Thromb Haemost; 2008 Aug; 6(8):1393-404. PubMed ID: 18513210
[TBL] [Abstract][Full Text] [Related]
15. Contribution of protease-activated receptors 1 and 4 and glycoprotein Ib-IX-V in the G(i)-independent activation of platelet Rap1B by thrombin.
Lova P; Campus F; Lombardi R; Cattaneo M; Sinigaglia F; Balduini C; Torti M
J Biol Chem; 2004 Jun; 279(24):25299-306. PubMed ID: 15078882
[TBL] [Abstract][Full Text] [Related]
16. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling.
Kim S; Foster C; Lecchi A; Quinton TM; Prosser DM; Jin J; Cattaneo M; Kunapuli SP
Blood; 2002 May; 99(10):3629-36. PubMed ID: 11986217
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of TRAP-6-induced platelet dense granule release by blockade of P2Y
Mitrugno A; Rigg RA; Laschober NB; Ngo ATP; Pang J; Williams CD; Aslan JE; McCarty OJT
Platelets; 2018 Jun; 29(4):383-394. PubMed ID: 28523947
[TBL] [Abstract][Full Text] [Related]
18. P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease.
Bierend A; Rau T; Maas R; Schwedhelm E; Böger RH
Br J Clin Pharmacol; 2008 Apr; 65(4):540-7. PubMed ID: 17995973
[TBL] [Abstract][Full Text] [Related]
19. Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition.
Badr Eslam R; Lang IM; Kaider A; Panzer S
Transl Res; 2013 May; 161(5):414-20. PubMed ID: 23313628
[TBL] [Abstract][Full Text] [Related]
20. The effect of P2Y12 inhibition on platelet activation assessed with aggregation- and flow cytometry-based assays.
Leunissen TC; Wisman PP; van Holten TC; de Groot PG; Korporaal SJ; Koekman AC; Moll FL; Teraa M; Verhaar MC; de Borst GJ; Urbanus RT; Roest M
Platelets; 2017 Sep; 28(6):567-575. PubMed ID: 27885904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
